No Data
Sanofi (SNY.US) has received approval for clinical trials of its novel dual antibody drug in China.
Recently, CDE announced that the Class 1 new drug SAR442970 injection declared by Sanofi (SNY.US) has obtained implied approval for clinical trials.
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Sanofi (SNY.US) has applied for the market launch of BTK inhibitors in China.
On December 30, the CDE official website showed that Sanofi (SNY.US) has had its market application for the BTK inhibitor Rilzabrutinib accepted.
How Is The Market Feeling About Sanofi?
RTW Biotech Opportunities Unit Closes Rights Deal With Sanofi, Buys Investigational Drug
